Related by context. All words. (Click for frequent words.) 67 multicentre randomized controlled 66 Randomized controlled 65 Initiated Phase 64 registrational Phase 64 multicenter randomized controlled 64 novel VDA molecule 64 EXPLORE Xa 63 Active Ulcerative Colitis 63 evaluating Actimmune 63 Intervention Effectiveness 62 Randomized Double blind 62 CIMZIA TM certolizumab pegol 62 Heterozygous Familial Hypercholesterolemia 62 ACCORD Lipid 62 Randomized Phase 62 Phase Ib IIa 62 evaluating satraplatin plus 62 approved incretin mimetic 62 CLARITY TIMI 62 Pivotal Phase III 62 Ophena TM 62 oral rivaroxaban 62 catheter occlusion 62 FOLFOX6 chemotherapy regimen 62 Placebo controlled 61 Primary Hypercholesterolemia 61 CHARM Added 61 Phase #b/#a clinical 61 retinal vein occlusion induced 61 evaluating tivozanib 61 Randomised 61 relapsed MM 61 Initiate Phase 61 CALERIE 61 Oral Fingolimod 61 Phase IIIb clinical 61 EURIDIS 61 ASTEROID 61 PEGINTRON REBETOL combination 61 Randomized Phase II 60 Combination REOLYSIN R 60 Newly Diagnosed Multiple Myeloma 60 Contrave# 60 Anturol TM 60 TAXUS VI 60 ADMIRE HF 60 By JENNIFER LEARN 60 LAB CGRP 60 dose escalation clinical 60 landmark ATHENA 60 Relapsing Multiple Sclerosis 60 naïve HCV 60 neutropenic sepsis 60 CATIE AD 60 Visit http:/www.Comtex.com 60 CINQUIL 60 Randomized Double Blind 60 headache nasopharyngitis 60 + Perifosine Evaluation 60 dependent kinase inhibitor 60 Trial Issue www.emagazine.com 60 multicentre randomized 60 Forodesine HCl 60 GOUT 60 treatment naive genotype 60 azilsartan medoxomil 60 ACCOMPLISH 60 GENASIS clinical 60 Recurrent Glioblastoma 60 Adis Medunjanin awaits 59 VICTOR E3 59 ExTRACT TIMI 59 Meets Primary Endpoint 59 serum phosphorous 59 HGS ETR1 mapatumumab 59 Phase 1a clinical 59 galiximab 59 neurologic progression 59 Omacetaxine 59 Multicenter Automatic Defibrillator Implantation 59 recombinant PSMA vaccine 59 ONTARGET 59 Controlled Trial 59 phase IIIb 59 HF ACTION 59 metastatic GIST 59 BRIM2 59 Mg Usa 59 beta carotene supplementation 59 undergoing elective percutaneous 59 CA9 SCAN 59 #mg/day [001] 59 RE LY ® 59 SPIRIT FIRST 59 Desvenlafaxine Succinate 59 Hypertensive Patients 59 lenalidomide Revlimid R 59 CYT# potent vascular disrupting 59 acarbose 59 Vidaza ® 59 TLK# 59 daily Infergen 59 VEGFR2 inhibitor 59 reactogenicity 59 humanized interleukin 6 59 R Saizen R 59 R lenalidomide 59 Myocardial Infarction Study 59 epoetin alpha 59 Study Evaluating 59 opioid naive 59 Phase 2b Clinical Trial 59 PLX STROKE targeting 59 contact Analytiqa 59 MKC# 59 daily subcutaneous injections 59 Val HeFT 59 RIO Diabetes 59 Prospective Randomized 59 placebo controlled clinical 59 Initiates Phase III 59 metastatic ocular 58 blinded randomized placebo controlled 58 Dose Escalation 58 Phase III AFFIRM 58 ongoing Phase 1b 58 sulfonylurea metformin 58 LymphoStat B belimumab 58 demonstrated antitumor activity 58 Darinaparsin 58 IMPACT DCM 58 Telithromycin 58 Pivotal Phase 58 Telik logo TELINTRA 58 Epanova 58 trial evaluating PRX# 58 using lactulose concomitantly 58 CALGB # [002] 58 Initiates Phase II 58 induced macular edema 58 Patients Treated With 58 unfractionated heparin UFH 58 Severe Sepsis 58 ANCHOR trial 58 Refractory Hodgkin Lymphoma 58 APEX PD 58 unique alkylating agent 58 pharmacodynamic effects 58 phase IIa clinical 58 evaluating mipomersen 58 Acute Myocardial Infarction 58 serotonin norepinephrine reuptake inhibitor 58 interferon gamma 1b 58 BRIM3 58 Syncria R 58 randomized controlled multicenter 58 Clinical Antipsychotic Trials 58 multicenter Phase III 58 ACTEMRA TM 58 Perifosine KRX 58 recurrent malignant glioma 58 AVN# Phase 58 weekly subcutaneous injections 58 Pooled Analysis 58 number NCT# ClinicalTrials.gov 58 HORIZONS AMI 58 Demonstrates Positive 58 BETAS 58 orally administered inhibitor 58 Relapsing Remitting Multiple Sclerosis 58 cromolyn sodium 58 oral prodrug 58 Cloretazine R 58 ENDEAVOR III 58 Secondary efficacy endpoints 58 Phase 2b kidney transplant 58 Placebo Controlled 58 evaluating Vectibix 58 fosbretabulin 58 Phase Ib clinical 58 hypercholesterolemic patients 58 everolimus eluting stents 58 Subgroup Analysis 58 abacavir lamivudine 58 Completes Patient Enrollment 58 evaluating satraplatin 58 ABSORB clinical 58 Aflibercept 58 refractory chronic lymphocytic 57 Adjuvant Treatment 57 Second Pivotal Phase 57 EmbraceAC 57 metformin sulfonylureas 57 cisplatin gemcitabine 57 LabCorp conducts clinical 57 urinary N telopeptide 57 brand ciclesonide HFA 57 RECORD1 57 Atherosclerotic 57 ENABLE Phase 2 57 Multicenter Randomized 57 Cloretazine R VNP#M 57 selective modulator 57 Androxal TM 57 alvespimycin 57 ToGA 57 somatostatin analog 57 CG# oncolytic virus 57 hyaluronidase enzyme 57 Phase IIb III 57 Empatic ™ 57 Initiate Phase III 57 visit http:/www.clinicaltrials.gov/ 57 GetGoal Phase III 57 dose atorvastatin 57 mg administered orally 57 ADVANCE PD 57 CARE HF 57 oral ridaforolimus 57 EDEMA3 57 hypoxia activated prodrug 57 ASCEND HF 57 Targretin capsules 57 Zoraxel 57 Kurylowicz trial 57 visilizumab 57 Apolipoprotein B 57 pharmacokinetics PK 57 ACAPODENE 57 NEVO RES 57 albiglutide 57 tribulations Groenveld 57 recurrent metastatic ovarian cancer 57 AP IMPACT Credibility 57 modified REGENESIS Phase IIb 57 bone marrow reticulin deposition 57 HYVET 57 interferon alpha IFN 57 severe hepatic insufficiency 57 II Clinical Trial 57 Phase III ADT 57 receiving INTRON 57 Maximum Tolerated Dose MTD 57 MADIT 57 OAB overactive bladder 57 foot ulcers DFU 57 HIV HCV coinfected 57 MAGE A3 ASCI 57 orally inhaled migraine 57 riociguat 57 Investigational Oral 57 Albuferon TM 57 ORMD 57 DIRECT Trial 57 triggers apoptosis programmed 57 albiglutide currently 57 ADVANCE ILLUMINATE 57 plus prednisone 57 Randomized placebo controlled 57 limiting toxicity DLT 57 INSPIRE Trial Phase III 57 CHAMPION PCI 57 Platelet Inhibition 57 Refractory Angina 57 teriflunomide 57 Phase III multicenter 57 First Patient Dosed 57 hormone refractory metastatic prostate 57 Multiple Ascending Dose 57 PERSEUS 57 trials RCTs 56 lomitapide 56 Cardiac Resynchronization 56 5 FU leucovorin 56 oral picoplatin 56 MVA MUC1 IL2 56 confirmatory clinical 56 hyperlipidemia hypertension 56 Romidepsin 56 MEK Inhibitor 56 NCT# ClinicalTrials.gov 56 #mg sodium #mg [002] 56 phase IIb clinical 56 STRIDE PD 56 CCX# B 56 Fondaparinux 56 Edge STudy 56 RE MODEL 56 interferon beta 1a infertility 56 Phase Ib II 56 rALLy 56 individualized cellular immunotherapy 56 multicenter Phase II 56 Long Lesion 56 oral nucleoside analogue 56 indolent follicular non 56 Subgroup analysis 56 Capesaris 56 Phase 1b clinical trials 56 Luramist TM 56 Teva Provides Update 56 Cloretazine ® 56 multicenter clinical 56 ZOLINZA 56 zonisamide SR 56 Trial Evaluating 56 Phase 1b clinical 56 NSABP B 56 TO AVOID PREGNANCY WHILE 56 RIO Lipids 56 acai pill 56 Relapsed Multiple Myeloma 56 Multicenter Randomized Double 56 Phase 2a clinical 56 Carotid Revascularization Endarterectomy vs. 56 relapsed myeloma 56 multicenter randomized placebo controlled 56 Naive Patients 56 resectable pancreatic cancer 56 Meridia sibutramine 56 rosuvastatin Crestor 56 clinical trials Archexin 56 pan histone deacetylase 56 ritonavir boosted 56 maximally tolerated dose 56 Cerebril TM 56 HOPE TOO 56 double blinded placebo 56 Achieves Primary Endpoint 56 desvenlafaxine succinate 56 KRN# 56 lowering triglyceride levels 56 adjuvant GIST 56 Pharmacokinetic 56 FUSILEV enhances 56 HGS ETR2 56 diabetic peripheral neuropathic DPN 56 COSTAR II 56 Bayer HealthCare Onyx Pharmaceuticals 56 maximal dose 56 dose escalation phase 56 LHRH receptor positive 56 SPEAR Study 56 venlafaxine XR 56 MEND CABG II 56 prospective multicenter randomized 56 keloid scarring 56 insulin sulfonylureas 56 acyclovir Lauriad R 56 Zemplar Capsules 56 Antitumor Activity 56 injectable diclofenac 56 Dapagliflozin 56 AN# topical anti 56 Initiates Enrollment 56 Xeloda ® 56 LUX Lung 56 Phase 2b Study 56 www.ingenuity.com 56 prospective randomized controlled 56 assessing T DM1 56 Callisto initiated 56 VICTOR E1 56 Antihypertensive 56 double blinded randomized 56 Kingman Ariz. awaiting 56 Patients Receiving 56 Pharmacokinetics PK 56 Phase IIB clinical 56 doxorubicin docetaxel 56 XL# SAR# 56 Suppository Hydrocortisone Acetate Rectal 56 PSMA ADC 56 pharmacokinetic PK study 56 Inc. NASDAQ HDIX 56 Completes Enrollment 56 relapsed ALL 56 Clinical Trial Evaluating 56 Gabapentin GR TM 56 IMPDH inhibitor 56 National Emphysema Treatment 56 Phase 1b trial 56 #beta 55 AVOREN 55 MEND CABG 55 comparing XIENCE V 55 pramlintide metreleptin combination 55 Ragweed Allergy 55 ® lenalidomide 55 Nesiritide 55 TASKi3 55 GISSI HF 55 forodesine 55 Motesanib 55 Raptiva ® 55 Toremifene 55 rhIGF-I/rhIGFBP-3 55 Phase IIIb 55 Phase III Clinical Trial 55 CLARITY study 55 randomized Phase IIb 55 CYP#A# CYP#D# 55 refractory NSCLC 55 antidepressants fluoxetine 55 treatment naïve genotype 55 Phase Ia 55 solid tumors ZYBRESTAT 55 designated HVTN 55 Darusentan 55 oral deforolimus 55 TNF Tumor Necrosis Factor 55 systemic anaplastic large 55 randomized controlled clinical 55 Bezielle 55 PSN# [002] 55 cluster randomized controlled 55 multicenter placebo controlled 55 Clinical Efficacy 55 Unstable Angina 55 pralatrexate injection folate analogue 55 Commences Phase 55 hypertrichosis occurred 55 EOquin TM phase 55 Curaxin CBLC# 55 myocardial infarction ventricular fibrillation 55 Prostate AdenoCarcinoma Treatment 55 Hormone Refractory Prostate Cancer 55 ataluren 55 Prolongs Survival 55 PROVENGE ® 55 humanized therapeutic 55 Huggins Cams Time 55 relapsed refractory multiple myeloma 55 Novel Oral 55 Complicated Skin 55 Relapsed Refractory 55 multicenter multinational 55 clinical trials Archexin ® 55 unresectable malignant mesothelioma UMM 55 multicenter randomized clinical 55 metastatic colorectal carcinoma 55 Heart Failure Patients 55 Phase IIb Trial 55 zileuton injection 55 Dose Limiting Toxicity DLT 55 randomized multicentre 55 PROSTVAC VF 55 paclitaxel cisplatin 55 candidates Azedra TM 55 davunetide intranasal AL 55 5 fluorouracil leucovorin 55 Jury Selection Resumes 55 Improves Outcomes 55 intravenous RSD# 55 acute mania 55 R roscovitine CDK cyclin 55 YOUR LOCAL ANIMAL SHELTER 55 ancrod 55 mitoxantrone plus 55 Improves Survival 55 CONQUER OB 55 CTA# Injection 55 LymphoStat B TM 55 Cloretazine 55 Preclinical Study 55 oral ghrelin agonist 55 comparator arm 55 clomipramine 55 sitagliptin Januvia 55 includes TOLAMBA TM 55 lead Aganocide compound 55 fallopian tube cancers 55 receiving XGEVA 55 PRIMO CABG 55 TAXUS ATLAS 55 MIST II 55 phase IIb study 55 RE LY 55 irbesartan 55 blinded placebo controlled 55 previously untreated follicular 55 ENDEAVOR IV clinical 55 AAG geldanamycin analog 55 papillary renal cell carcinoma 55 blinded randomized controlled 55 stage IIIb IV 55 evaluating MGCD# [002] 55 inflammatory PDE 55 relapsing multiple sclerosis 55 PARGLUVA 55 finasteride Proscar 55 VADT 55 thorough QT 55 davalintide 55 Initiates Phase 55 Phase #b/#a trial 55 dimebon latrepirdine 55 multicenter randomized 55 Intervention Effectiveness CATIE 55 Pemetrexed 55 Mycophenolate Mofetil 55 AOD# [002] 55 Enzastaurin 55 moderate hepatic impairment 55 Pivotal Phase II 55 ascending dose study 55 Plaque Psoriasis 55 SILENOR 55 XL# anticancer compounds 55 non constipating irritable 55 Randomized Evaluation 55 Phase III VISTA 55 Silodosin 55 TMC# C# 55 placebo controlled Phase III 55 TASKi2 55 heFH 55 PEGINTRON TM 55 pharmacogenomic translational research 55 Phase 2b Trial 55 zoledronic acid Reclast 55 Teriflunomide 55 EDEMA3 trial 55 Clolar ® 55 BOLDER II 55 PROTEGE 55 CEL SCI Phase III 55 HCV SPRINT 55 signal detection CTSD 55 noninferior 55 Randomized Controlled 55 Testosterone MDTS R 55 dirucotide MBP# 55 R sorafenib tablets 55 Dupuytren Disease 55 Investigational Treatment 55 Ovitrelle R Serostim 55 inecalcitol 54 Hsp# Inhibitor 54 Vidaza R 54 PDX pralatrexate 54 Soft Tissue Sarcoma 54 Serada 54 steroid refractory 54 develop HBV reactivation 54 SPRYCEL ® 54 dual endothelin receptor antagonist 54 relapsing remitting MS RRMS 54 Phase 2a Clinical Trial 54 multicenter prospective 54 Diffuse Large B 54 ADONIS 54 IMPACT DCM clinical 54 receiving chemoradiation therapy 54 FEMALES SHOULD BE ADVISED 54 Exelixis compounds 54 Hypertrophy 54 RLAI 54 kidney urologic 54 Dose Ranging 54 Non Alcoholic Steatohepatitis 54 velafermin 54 Liraglutide Effect 54 Trandolapril 54 VESTASYNC 54 donepezil Aricept 54 analgesic efficacy 54 HALTS 54 particularly SANCTURA XR 54 Controlled Study 54 Pegylated Liposomal Doxorubicin 54 Proellex TM 54 COMFORT II 54 XZK 54 icatibant 54 #mg dosing 54 nab paclitaxel 54 Vicriviroc 54 advanced metastatic renal 54 Long Term Efficacy 54 CYP#A# substrate 54 TM Drug Eluting 54 metastatic castration resistant 54 pharmacokinetic parameters 54 antiretroviral naïve 54 Attorney Jonathan Skrmetti 54 monoclonal antibody conjugated 54 Testosterone MDTS ® 54 gwahn DEE' kay 54 placebo controlled multicenter 54 Randomized Study 54 AIM HIGH 54 metastatic colorectal 54 RSD# oral 54 eosinophilic asthma 54 recurrent glioblastoma multiforme 54 phase Ib clinical 54 Lipitor #mg 54 Amgen Neulasta R 54 Glycopyrrolate 54 Begins Dosing 54 DCCR 54 Immunomodulatory 54 metastatic pancreatic 54 Metastatic Melanoma 54 Proc Am Soc 54 aflibercept VEGF Trap 54 Elagolix 54 Vidaza azacitidine 54 multicentre randomized double 54 Double Blind Placebo 54 metastatic androgen independent 54 PYY #-# 54 dasatinib Sprycel ® 54 lintuzumab SGN 54 ATRA IV 54 Epothilone D 54 investigational protease inhibitor 54 alfa 2a 54 Sustained Efficacy 54 aplindore 54 Closing Arguments Begin 54 EVEREST II 54 phase IIa 54 evaluating T DM1 54 Confirmatory Phase 54 Oral Calcitonin 54 asymptomatic metastatic 54 tarenflurbil 54 Pruvel TM 54 randomized #:#:# 54 Anti VEGF 54 docetaxel Taxotere ® 54 IIa trial 54 Metabolic Efficiency 54 MKC# MT 54 Monotherapy 54 ChronVac C 54 PROVENGE sipuleucel T 54 ascending dose 54 Phase IIA 54 octreotide implant 54 phase Ib 54 SIMPADICO 54 Folfox 54 DASISION 54 paclitaxel poliglumex 54 recurrent glioma 54 Pivotal Trial 54 anti arrhythmic drug 54 doxorubicin cyclophosphamide 54 Cannabinor 54 Flu Cy 54 Chronic Hepatitis C 54 active comparator 54 PNP inhibitor 54 dyslipidemia hypertension diabetes 54 Daclizumab 54 paricalcitol 54 MGd 54 lexidronam injection 54 cyclophosphamide doxorubicin vincristine 54 including eniluracil ADH 54 ThermoDox ® clinical 54 Demonstrates Efficacy 54 Ereska 54 receptor tyrosine kinase inhibitor 54 HGS ETR1 54 multicenter Phase 54 Prosecution Rests Case 54 Tarceva TM 54 LibiGel Phase III 54 undergoing hematopoietic stem 54 PREVENT IV 54 Dose Finding 54 Renal Cell Carcinoma 54 Serevent salmeterol 54 Irbesartan 54 prospective multicenter 54 Aeolus Pharmaceuticals Announces 54 Engerix B 54 Albuferon Phase 54 highly selective inhibitor 54 AKT inhibitor 54 randomized blinded 53 Crofelemer budesonide foam 53 citalopram Celexa 53 Synta Announces 53 olmesartan 53 Phase III Pivotal 53 myopic CNV 53 Tumor Response 53 Therapeutic Efficacy 53 ENDEAVOR II 53 Initiates Phase 2b 53 mg qd 53 Bosutinib 53 Ferinject R 53 plus dacarbazine 53 generation purine nucleoside 53 novel orally inhaled 53 ENESTnd 53 mecarbil 53 personalized cellular immunotherapy 53 ECASS 53 metreleptin 53 PEGylated Fab fragment 53 Phase III psoriasis 53 ZACTIMA 53 severe oral mucositis 53 hyperplasia BPH 53 subcutaneous methylnaltrexone 53 Metastatic Colorectal Cancer 53 novel chimeric natriuretic 53 virus HCV protease inhibitor 53 worsening thrombocytopenia 53 multicentre prospective 53 REGENESIS Phase IIb 53 Prostate Cancer Prevention 53 Pivotal Study 53 HuMax EGFr 53 SUTENT ® 53 Lopid 53 known dihydropyrimidine dehydrogenase 53 Completes Dosing 53 metastatic hormone refractory 53 Triapine R 53 Antigen Specific 53 placebo controlled randomized 53 Reduce Cardiovascular 53 Phase IIb randomized 53 tenofovir emtricitabine 53 Phase III Trial 53 compound INCB# 53 Cholesterol Levels SPARCL 53 Amoxicillin PULSYS Phase III 53 irinotecan doxorubicin oxaliplatin paclitaxel 53 evaluating picoplatin 53 Presents Positive 53 pregabalin Lyrica 53 TRITON TIMI 53 Sibutramine Cardiovascular Outcomes 53 Cancidas 53 echinacea tablets 53 refractory acute myeloid 53 randomized multicenter 53 3 registrational trial 53 dasatinib Sprycel 53 THAT ARE DIFFICULT TO 53 injectable enzyme 53 rALLy trial 53 rALLy clinical trial 53 neratinib 53 ONTARGET R 53 Chronic Heart Failure 53 Alequel 53 5 Fluorouracil 53 Protease Inhibitors 53 intravenous picoplatin 53 lumiliximab 53 #I TM# 53 Previously Treated 53 treat secondary hyperparathyroidism 53 ISTODAX ® 53 Ovarian Cancer Screening 53 placebo controlled dose escalation 53 sunitinib Sutent ® 53 cladribine Cladribine Tablets 53 Prostate Lung Colorectal 53 NDA Submission 53 FOLOTYN ® 53 PROTECT AF 53 http:/www.investorsobserver.com/MUQuote2 53 Vascular Disrupting Agent 53 See WARNINGS 53 pravastatin Pravachol 53 prospective randomized placebo 53 budesonide foam 53 Dextofisopam Phase 2b 53 AVERROES 53 convulsive disorders 53 obesity dyslipidemia 53 Acute Decompensated Heart Failure 53 pharmacokinetic characteristics 53 Fluvastatin 53 Archexin 53 NS5B polymerase 53 Peginterferon Alfa 2a 53 Ribavirin causes 53 Glatiramer Acetate 53 imetelstat GRN#L 53 PEG IFN 53 Cutaneous T 53 HCV RESPOND 2 53 nilotinib Tasigna ® 53 Humanized Anti 53 refractory metastatic colorectal cancer 53 Multicenter 53 oral Janus kinase 53 Advanced Melanoma 53 APPRAISE 53 PRoFESS 53 Submits Biologics License Application 53 MADIT II 53 C1 INH deficiency 53 prostate cancer HRPC 53 erlotinib Tarceva ® 53 Ziprasidone 53 BR.# 53 ruxolitinib 53 Phase III Psoriasis 53 unresectable Stage III 53 Acute Exacerbations 53 dosage regimens 53 Intravitreal 53 Parathyroid Hormone 53 Initiate Phase II 53 pertuzumab 53 resistant hormone refractory 53 gemcitabine carboplatin 53 Pharmacokinetic Study 53 briakinumab 53 SORT OUT III 53 BLOOM Behavioral modification 53 Safinamide 53 blind randomized controlled 53 DEB# 53 Closing Arguments Heard 53 #mg ATC 53 BCG refractory carcinoma 53 Saxagliptin 53 Randomized Clinical Trial 53 FDA APPROVES 53 Aliskiren 53 arsenic trioxide injection 53 Node Positive 53 Commence Phase 53 UPLYSO 53 incyclinide 53 Sapacitabine 53 R ferumoxytol Injection 53 occlusion PAO 53 CYP#A# isoenzyme 53 Castration Resistant Prostate Cancer 53 REMINYL ® 53 tramiprosate Alzhemed TM 53 dextromethorphan quinidine 53 FDA defined valvulopathy 53 Phase IIb clinical 53 ziprasidone Geodon 53 Pralatrexate 53 EDEMA4 53 reslizumab 53 MIRAPEX ER 53 ISAR TEST 53 irregular quivering 53 Eszopiclone 53 Motexafin Gadolinium 53 prospective randomized multicenter 53 non splenectomized 53 HATC follow 53 midstage clinical 53 TEC #OL 53 Phase III HEAT 53 Dose Ranging Study 53 Mylan Receives Approval 53 cell carcinoma RCC 53 Pyridorin 53 Malignant Glioma 53 Degarelix 53 PRIMO CABG2 53 Previously Untreated 53 Presents Preclinical Data 53 selective phosphodiesterase 53 placebo controlled Phase 53 Study Shows Promise 53 Corlux 53 PFO migraine 53 Fulvestrant 53 ELACYT 53 ® natalizumab 53 Hepsera adefovir dipivoxil 53 COPEGUS R 53 nucleotide analogue 52 Demonstrates Sustained 52 Myelodysplastic Syndrome MDS 52 Alpha Tocopherol Beta Carotene 52 hoFH 52 TBC# 52 Oncolytic Reovirus 52 CLORETAZINE TM VNP#M 52 Hepatotoxicity 52 Glufosfamide 52 Clinical Validation 52 Empatic TM 52 lorcaserin Phase 52 subcutaneous PRO 52 ACTIVE W 52 Neovascular Age Related Macular 52 combines Zetia 52 ORAL Sync 52 Zilver PTX Drug Eluting 52 Phase III Pivotal Trial 52 Picoplatin Efficacy After 52 subcutaneous enoxaparin 52 Predict Response 52 cetrorelix pamoate 52 Phase III randomized controlled 52 alendronate Fosamax 52 atherosclerosis rheumatoid arthritis 52 IL# PE#QQR 52 evaluating Xcytrin 52 Alimentary Tract 52 QLT# 52 tesofensine 52 relapsed MCL 52 Dyloject TM 52 canakinumab 52 fluvastatin 52 delivers fluocinolone acetonide FA 52 irinotecan cisplatin 52 Jury Hears Closing Arguments 52 candidate XP# 52 preclinical pharmacokinetic 52 REVIVE Diabetes 52 peginterferon alpha 2a 52 pseudobulbar affect PBA 52 Deforolimus 52 PANVAC VF 52 included exfoliative dermatitis 52 Krenwinkel admitted 52 liposomal formulation 52 randomized dose escalation 52 Dose Escalation Study 52 pioglitazone hydrochloride 52 reputed mobster Joseph 52 myelodysplastic myeloproliferative diseases 52 Prednisone Against Refractory 52 mGluR5 negative 52 OncoVEX GM CSF 52 CRLX# 52 mapatumumab 52 Known hypersensitivity 52 fistulizing Crohn disease 52 Launches Generic Version 52 topiramate Topamax 52 Intravenous immunoglobulin 52 prospective observational studies 52 epothilone KOS 52 Tyrima 52 ropinirole Requip 52 TG MV 52 CAMMS# 52 Shows Statistically Significant 52 randomized Phase III 52 Efficacy Trial 52 Initiates Clinical Trial 52 GREATER HAMILTON 'S 52 TMC# r 52 de novo kidney transplant 52 metastatic HRPC 52 registrational clinical 52 CLOTS 52 lawmaker Hosseini Sobhaninia 52 treat benign prostatic 52 endoscopic remission 52 d l leucovorin 52 pretransplant 52 Opening Arguments Begin 52 Pivotal Clinical Trial 52 steroid refractory ulcerative 52 Oral Insulin Capsule 52 Shows Promising 52 GVAX ® 52 AML MDS 52 Glucosamine Chondroitin Arthritis 52 tolevamer 52 opioid induced bowel dysfunction 52 Intervention Trial 52 oral sapacitabine 52 Submits NDA 52 AIR CF1 52 Platinol ® 52 Femara letrozole 52 Metastatic Renal Cell Carcinoma 52 phase IIb III 52 Phase III placebo controlled 52 Pharmacodynamics 52 recurrent metastatic 52 Dementia Related Psychosis 52 antibody MAb 52 corticosteroid dexamethasone 52 PPAR gamma agonist 52 controlled multicenter 52 Xelox 52 lapatinib Tykerb 52 ® bortezomib 52 TOLAMBA 52 immunomodulatory agents